A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
ObesityOverweight
Interventions
DRUG

Orforglipron

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (29)

10021

Weill Cornell Medical College, New York

27408

PharmQuest Life Sciences, LLC, Greensboro

29607

Tribe Clinical Research, LLC, Greenville

30291

Rophe Adult and Pediatric Medicine/SKYCRNG, Union City

33165

New Horizon Research Center, Miami

35124

Cahaba Research - Pelham, Pelham

35242

Cahaba Research, Birmingham

37421

WR-Clinsearch, LLC, Chattanooga

39069

Prime Health and Wellness/SKYCRNG, Fayette

40213

L-MARC Research Center, Louisville

48098

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

58104

Lillestol Research, Fargo

63303

StudyMetrix Research, City of Saint Peters

73069

Alliance for Multispecialty Research, LLC, Norman

75149

Southern Endocrinology Associates, Mesquite

75230

Velocity Clinical Research, Dallas, Dallas

75231

North Texas Endocrine Center, Dallas

77043

Biopharma Informatic, LLC, Houston

77079

PlanIt Research, PLLC, Houston

77401

The University of Texas Health Science Center at Houston, Bellaire

83404

Rocky Mountain Clinical Research, Idaho Falls

89128

Palm Research Center Tenaya, Las Vegas

89148

Palm Research Center Sunset, Las Vegas

91978

Encompass Clinical Research, Spring Valley

92701

Southern California Dermatology, Inc., Santa Ana

92780

University Clinical Investigators, Inc., Tustin

00717

Puerto Rico Medical Research, Ponce

00694

Wellness clinical Research Vega Baja, Vega Baja

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06584916 - A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Biotech Hunter | Biotech Hunter